Asterias Biotherapeutics (AST) Reports In-Line Q4 EPS

Asterias Biotherapeutics (NYSE: AST) reported Q4 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $608 thousand versus the consensus estimate of $1.07 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• JD.com, Inc (JD) PT Lowered to $37 at Macquarie ahead of earnings
• Disney initiated at Buy as analyst sees parks, streaming fueling next growth phase